Bgm (BGM) Current Leases (2020 - 2025)

Bgm (BGM) posted quarterly Current Leases of $240943.0 for Q3 2025, up 136.65% quarter-over-quarter from $101814.0 in Q1 2025.

Bgm (BGM) Current Leases (2020 - 2025) Analysis & Trends

Bgm (BGM) has reported Current Leases for 6 consecutive years, with $240943.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Current Leases changed N/A year-over-year to $240943.0; the TTM figure through Sep 2025 stood at $240943.0 (changed N/A YoY), while the FY2025 annual figure was $240943.0, changed N/A from the prior year.
Current Leases improved to $240943.0 in Q3 2025 per BGM's latest filing, from $101814.0 in the prior quarter.
Across five years, Current Leases topped out at $44.7 billion in Q1 2022 and bottomed at $23859.0 in Q3 2022.
Historically, Current Leases has averaged $8.8 billion across 5 years, with a median of $92451.5 in 2024.
Annual changes were most pronounced in 2023 — Current Leases jumped 208.31% — and 2024, when it plunged 100.0%.
Bgm's Current Leases stood at $55847.0 in 2021, then tumbled by 57.28% to $23859.0 in 2022, then surged by 208.31% to $73560.0 in 2023, then rose by 12.95% to $83089.0 in 2024, then soared by 189.98% to $240943.0 in 2025.
Business Quant data shows BGM's Current Leases at $240943.0 in Q3 2025, $101814.0 in Q1 2025, and $83089.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	-
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	-
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Bgm	30.61 Mn	20.79 Mn	-	240,943.00

Download Data